71 related articles for article (PubMed ID: 17151376)
1. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.
Grey A; O'Sullivan S; Reid IR; Browett P
N Engl J Med; 2006 Dec; 355(23):2494-5. PubMed ID: 17151376
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
Ianotto JC; Tempescul A; Amet Y; Grall P; Dalbies F; Eveillard JR; Guillerm G; Berthou C
Am J Hematol; 2012 Apr; 87(4):437-9. PubMed ID: 22287505
[No Abstract] [Full Text] [Related]
3. Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.
Yang KH; Park SY; Park SW; Lee SH; Han SB; Jung WK; Kim SJ
J Bone Miner Metab; 2010 Nov; 28(6):713-8. PubMed ID: 20607326
[TBL] [Abstract][Full Text] [Related]
4. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Berman E; Nicolaides M; Maki RG; Fleisher M; Chanel S; Scheu K; Wilson BA; Heller G; Sauter NP
N Engl J Med; 2006 May; 354(19):2006-13. PubMed ID: 16687713
[TBL] [Abstract][Full Text] [Related]
5. Imatinib and altered bone and mineral metabolism.
Owen S; Hatfield A; Letvak L
N Engl J Med; 2006 Aug; 355(6):627; author reply 628-9. PubMed ID: 16899786
[No Abstract] [Full Text] [Related]
6. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
Osorio S; Noblejas AG; Durán A; Steegmann JL
Am J Hematol; 2007 May; 82(5):394-5. PubMed ID: 17117416
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
9. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
10. Imatinib and altered bone and mineral metabolism.
Joensuu H; Reichardt P
N Engl J Med; 2006 Aug; 355(6):628; author reply 628-9. PubMed ID: 16903020
[No Abstract] [Full Text] [Related]
11. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy].
Sumi M; Tauchi T; Shimamoto T; Sshida G; Nakajima A; Ito Y; Ohyashiki K
Rinsho Ketsueki; 2002 Sep; 43(9):868-70. PubMed ID: 12412295
[TBL] [Abstract][Full Text] [Related]
13. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
14. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
15. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
Sharma P; Kumar L; Mohanty S; Kochupillai V
Ann Hematol; 2010 Mar; 89(3):241-7. PubMed ID: 19714331
[TBL] [Abstract][Full Text] [Related]
16. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
[TBL] [Abstract][Full Text] [Related]
18. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
[TBL] [Abstract][Full Text] [Related]
19. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
20. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.
Jönsson S; Olsson B; Ohlsson C; Lorentzon M; Mellström D; Wadenvik H
Haematologica; 2008 Jul; 93(7):1101-3. PubMed ID: 18508797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
